Currencies Hit Lilly’s Emerging Market Sales But Japan Brighter
This article was originally published in PharmAsia News
Chinese government moves to cut drug costs are further squeezing pharma multinationals including Lilly, which was also hit hard by currency effects in its emerging markets business last quarter. But the US firm’s outlook in Japan seems brighter, based on new oncology developments.
Register for our free email digests: